Controlled-Release CNP Agonist for Reduced Hypotension Risk

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

The short half-life of CNP-22 and its extensive inactivation in subcutaneous tissue necessitate continuous infusion, leading to cardiovascular side-effects such as hypotension, making it challenging to administer efficaciously in pediatric populations.

Innovation Solution

A controlled-release CNP agonist with a release half-life of at least 6 hours, reducing side-effects and allowing higher doses for safer and more convenient treatment.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If continuous infusion of CNP is administered to achieve therapeutic efficacy, then the dwarfism is normalized, but cardiovascular side-effects such as hypotension occur

Engineering Contradiction:

Improvetherapeutic efficacyVSAvoidcardiovascular side-effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent introduces a controlled-release formulation as an intermediary carrier that delivers CNP gradually over time. This mediator system allows the therapeutic agent to be released slowly, maintaining effective blood levels without causing sudden spikes that lead to hypotension and other cardiovascular side-effects.

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The controlled-release formulation implements periodic action by releasing CNP in controlled intervals over an extended period. This periodic delivery pattern maintains therapeutic efficacy while avoiding continuous high-dose exposure that causes cardiovascular adverse effects.

Inventive Principle:

Principle #19Periodic action

2Reliability

If higher doses of CNP are administered to increase drug exposure, then therapeutic efficacy is improved, but cardiovascular side-effects such as hypotension increase

Engineering Contradiction:

Improvetherapeutic efficacyVSAvoidhypotension

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent changes the parameter of drug release kinetics from immediate to controlled-release. This parameter change allows higher total doses to be administered over extended periods while maintaining safe blood pressure levels, as the controlled-release mechanism prevents rapid increases in plasma concentration that would cause hypotension.

Inventive Principle:

Principle #35Parameter changes

3Ease of operation

If CNP is administered subcutaneously to avoid intravenous infusion, then convenience is improved, but the drug is extensively inactivated

Engineering Contradiction:

Improveadministration convenienceVSAvoiddrug bioavailability

Core Design Contradiction:

Ease of operationVSReliability

Solution Approach 1:

The controlled-release formulation acts as a protective intermediary that shields CNP from rapid inactivation in subcutaneous tissue. This mediator system allows subcutaneous administration to proceed while maintaining adequate bioavailability through controlled, gradual release that outpaces local degradation mechanisms.

Inventive Principle:

Principle #24Intermediary (Mediator)

Data Source

PatentUS12544428B2Controlled-release CNP agonists with reduced side-effects

Publication Date: 2026.02.10 ASCENDIS PHARMA GROWTH DISORDERS AS

AI summary

The present invention relates a pharmaceutical composition comprising a controlled-release CNP agonist which reduces CNP agonist-associated side-effects, the use of such controlled-release CNP agonist and to methods of treatment.